Histone deacetylase as emerging pharmacological therapeutic target for neuropathic pain: From epigenetic to selective drugs
CNS Neuroscience & Therapeutics · 2024-05 · 30 (5)
DOI: 10.1111/cns.14745 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 07.05.2024. Verfasst von Wencui Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Pain Medicine, Hubei Key Laboratory of Geriatric Anesthesia and Perioperative Brain Health, and Wuhan Clinical Resea…. Hauptthemen laut MEDLINE: Epigenesis, Genetic, Histone Deacetylase Inhibitors, Histone Deacetylases, Neuralgia. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Neuropathic pain remains a formidable challenge for modern medicine. The first‐line pharmacological therapies exhibit limited efficacy and unfavorable side effect profiles, highlighting an unmet need for effective therapeutic medications. The past decades have witnessed an explosion in efforts to translate epigenetic concepts into pain therapy and shed light on epigenetics as a promising avenue for pain research. Recently, the aberrant activity of histone deacetylase (HDAC) has emerged as a key mechanism contributing to the development and maintenance of neuropathic pain.
Aims
In this review, we highlight the distinctive role of specific HDAC subtypes in a cell‐specific manner in pain nociception, and outline the recent experimental evidence supporting the therapeutic potential of HDACi in neuropathic pain.
Methods
We have summarized studies of HDAC in neuropathic pain in Pubmed.
Results
HDACs, widely distributed in the neuronal and non‐neuronal cells of the dorsal root ganglion and spinal cord, regulate gene expression by deacetylation of histone or non‐histone proteins and involving in increased neuronal excitability and neuroinflammation, thus promoting peripheral and central sensitization. Importantly, pharmacological manipulation of aberrant acetylation using HDAC‐targeted inhibitors (HDACi) has shown promising pain‐relieving properties in various preclinical models of neuropathic pain. Yet, many of which exhibit low‐specificity that may induce off‐target toxicities, underscoring the necessity for the development of isoform‐selective HDACi in pain management.
Conclusions
Abnormally elevated HDACs promote neuronal excitability and neuroinflammation by epigenetically modulating pivotal gene expression in neuronal and immune cells, contributing to peripheral and central sensitization in the progression of neuropathic pain, and HDACi showed significant efficacy and great potential for alleviating neuropathic pain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology and Pain Medicine, Hubei Key Laboratory of Geriatric Anesthesia and Perioperative Brain Health, and Wuhan Clinical Research Center for Geriatric Anesthesia, Tongji Hospital, Tongji Medical C…
ORCID-Profile: Xianwei Zhang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, W., Jiao, B., Yu, S., Zhang, C., Zhang, K., Liu, B., & Zhang, X. (2024). Histone deacetylase as emerging pharmacological therapeutic target for neuropathic pain: From epigenetic to selective drugs. CNS Neuroscience & Therapeutics, 30(5). https://doi.org/10.1111/cns.14745
Vancouver
Zhang W, Jiao B, Yu S, Zhang C, Zhang K, Liu B, et al. Histone deacetylase as emerging pharmacological therapeutic target for neuropathic pain: From epigenetic to selective drugs. CNS Neuroscience & Therapeutics. 2024;30(5). doi:10.1111/cns.14745
BibTeX
@article{Zhang2024,
author = {Zhang, Wencui and Jiao, Bo and Yu, Shangchen and Zhang, Caixia and Zhang, Kaiwen and Liu, Baowen and Zhang, Xianwei},
title = {Histone deacetylase as emerging pharmacological therapeutic target for neuropathic pain: From epigenetic to selective drugs},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
volume = {30},
number = {5},
doi = {10.1111/cns.14745}
}
EUVIMED